www.nature.com
3 months agoMedicine
Alzheimer's Drug with Modest Benefits Gets Green Light from FDA Advisers
Donanemab, a drug for Alzheimer's, gains unanimous approval for treating cognitive decline in early-stage patients but has limited effects and usage restrictions. [ more ]